Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.50 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.50 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.50 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.50 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.50 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.50 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.50 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27569873 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| SCHEMBL27030505 | 0.98 | GABRP (0.52) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| SCHEMBL5163 | 0.98 | GABRP (0.52) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| Bromide SCHEMBL11553713 | 0.95 | CHRNB2 (0.50) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| Potassium SCHEMBL31108386 | 0.95 | CHRNB2 (0.50) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL14697147 | 0.92 | SMN1; SMN2 (0.46) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| SCHEMBL13406360 | 0.90 | SMN1; SMN2 (0.47) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| SCHEMBL13406359 | 0.90 | SMN1; SMN2 (0.47) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| SCHEMBL6978531 | 0.90 | SMN1; SMN2 (0.47) | CHRNB2CHRNA4GABRPGABRDGABRA1 | |
| SCHEMBL13406367 | 0.88 | SMN1; SMN2 (0.50) | CHRNB2CHRNA4GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111484444-B | Synthesis method of N-benzyl-4-piperidine formaldehyde | 常州大学 | 2021-07-30 | — | — | CN | claimed |
| CN-111484444-A | Synthesis method of N-benzyl-4-piperidine formaldehyde | 常州大学 | 2020-08-04 | — | — | CN | claimed |
| CN-107188921-A | The preparation method of abiraterone derivative and its new solid-state form and purposes | 四川海思科制药有限公司 | 2017-09-22 | — | — | CN | claimed |
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025228902-A1 | HETEROCYCLIC ACIDS AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| EP-4608820-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-120077034-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| EP-3746447-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024233544-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-114539133-B | Method for preparing prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 鲁南制药集团股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-5304645-A | Colored or fluorescent labels | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-19 | — | — | US | disclosed |
| US-5182399-A | Process for preparing piperidinyl benzimidazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-01-26 | — | — | US | disclosed |
| US-4954630-A | COLORIMETRIC OR FLUORESCENT ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-09-04 | — | — | US | disclosed |
| EP-0363963-A1 | Piperidinyl benzimidazoles as antihistamines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-18 | — | — | EP | disclosed |
| US-4908372-A | Antihistaminic piperidinyl benzimidazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | disclosed |
| US-4870083-A | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0317997-A2 | 1,4-Disubstituted-piperidinyl compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0075737-A1 | N-Chlorocarbonyl-amino-acid esters, process for their preparation and their use | Degussa Aktiengesellschaft (DE) | 1983-04-06 | — | — | EP | disclosed |
| EP-0000167-A1 | 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them. | Krogsgaard-Larsen, Povl (DK) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | ARSA, SULT1A1, SULT2A1 | GABRP 1726/4885GABRD 3485/4885GABRA1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.